RemeGen (HKG:9995, SHA:688331) reported a net loss attributable to shareholders of 291.0 million yuan for the quarter ended Sept. 30, according to a Tuesday filing with the Hong Kong bourse.
The loss per share for the quarter was 0.54 yuan.
Revenue was 467.1 million yuan, a 34.60% increase from the prior-year quarter.
Hong Kong shares of the biopharmaceutical company gained 3% in morning trade Wednesday, while its Shanghai shares gained nearly 4%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。